A Study of A RSV Vaccine When Given Together With Tdap in Healthy Nonpregnant Women Aged Between 18 and 49 Years

Final Report: A Phase 2b, Placebo-Controlled, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine When Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Tdap) in Healthy Nonpregnant Women 18 Through 49 Years of Age

Category & Conditions:
Vaccine-related Conditions
Medicine:
PF-06928316
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C3671004
Open Plain Language Summary Result:Click here